Catalyst
Slingshot members are tracking this event:
Summit Therapeutics (SMMT) set to begin Phase 3 trial on antibiotic Ridinilazole in treating C. difficile 1Q 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SMMT | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 13, 2019
Occurred Source:
https://www.summitplc.com/app/uploads/2019/02/2019_RNS_06-RiCoDIFy-Programme-Initiation-FINAL.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
C. Difficile, Ridinilazole, Phase 3 Study
